welcure drugs & pharmaceuticals has scheduled a meeting of its Board of Directors for Friday, May 29, 2026. The meeting will be held at the company's registered office to discuss and approve key financial documents for the fiscal year ending March 31, 2026.

Agenda for the Meeting

The primary agenda for the board meeting includes the consideration and approval of the audited financial results for the quarter and year ended March 31, 2026. Additionally, the board will take on record the audit report of the statutory auditors associated with these results.

Financial Statements Approval

The directors are also expected to consider and approve the audited financial statements for the year ended March 31, 2026. This encompasses the balance sheet as of that date, along with the statement of profit and loss, cash flow statement, and accompanying notes.

Regulatory Compliance

The intimation of the board meeting was made in compliance with Regulation 29(1)(a) and (e) of the SEBI (LODR) Regulations, 2015. The company confirmed that it is in the process of filing the corporate announcement in XBRL format within the stipulated time, which will subsequently be hosted on its official website.

The meeting notice, signed by Director Chintan Didawala Ganpat, was dispatched to BSE Limited on May 22, 2026.

Welcure drugs & pharmaceuticals Limited has submitted its mandatory confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to the Bombay Stock Exchange. The filing covers the fourth quarter and annual year ended March 31, 2026, representing a key regulatory compliance requirement for listed companies.

Regulatory Compliance Details

The certificate was submitted on April 3, 2026, and confirms that no physical share certificates were received for dematerialization of securities from the depository participant during the specified period. This certification is issued by the company's Registrar and Transfer Agent, Skyline Financial Services Pvt Ltd, and serves as confirmation of compliance with SEBI's depositories regulations.

Company Information

Welcure Drugs & Pharmaceuticals Limited operates from its registered office located at Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, East Delhi, New Delhi. The company is incorporated under CIN: L68100DL1996PLC227773 and maintains its corporate website at welcure.co.in.

Certification Process

The confirmation certificate was signed by Parveen Sharma, Authorised Signatory of Skyline Financial Services Private Limited, on April 1, 2026. The document specifically states that no physical share certificates were received for dematerialization of equity shares during the quarter ended March 31, 2026. This certification process ensures transparency in the company's share transfer and dematerialization activities.

Management Authorization

The submission to BSE was authorized by Chintan Didawala Ganpat, Managing Director and CFO of Welcure Drugs & Pharmaceuticals Limited, with DIN: 11088268. The digital signature was applied on April 3, 2026, at 15:15:30 +05'30', confirming the authenticity of the regulatory filing. This demonstrates the company's commitment to maintaining proper corporate governance and regulatory compliance standards.